Syndax to Announce Fourth Quarter and Year-end 2016 Financial Results and Host Conference Call and Webcast on March 2, 2017
February 16 2017 - 7:00AM
Syndax (Nasdaq:SNDX) announced today that it will release its
fourth quarter 2016 financial results on Thursday, March 2, 2017,
after the close of the U.S. financial markets.
In connection with the earnings release,
Syndax's management team will host a conference call and live audio
webcast at 4:30 p.m. ET on Thursday, March 2, 2017, to discuss the
Company's financial results and provide a general business
update.
The live audio webcast and accompanying slides
may be accessed through the Events & Presentations page in the
Investors section of the Company's website at www.syndax.com.
Alternatively, the conference call may be accessed through the
following:
Conference ID: 63366789 Domestic Dial-in Number: 1-855-251-6663
International Dial-in Number: 281-542-4259 Live webcast:
http://edge.media-server.com/m/p/6txfuwhh
For those unable to participate in the
conference call or webcast, a replay will be available for 30 days
on the Investors section of the Company's website,
www.syndax.com.
About Syndax Pharmaceuticals, Inc. Syndax is a
clinical stage biopharmaceutical company focused on developing an
innovative pipeline of combination therapies in multiple cancer
indications. Our lead product candidate, entinostat, which was
granted Breakthrough Therapy designation by the FDA following
positive results from our Phase 2b clinical trial, ENCORE 301, is
currently being evaluated in a Phase 3 clinical trial for advanced
hormone receptor positive, human epidermal growth factor receptor 2
negative breast cancer. Syndax is developing entinostat, which has
direct effects on both cancer cells and immune regulatory cells,
and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the
body's immune response on tumors that have shown sensitivity to
immunotherapy. Entinostat is being evaluated as a combination
therapeutic in Phase 1b/2 clinical trials with Merck & Co.,
Inc. for non-small cell lung cancer and melanoma; with Genentech,
Inc. for TNBC; and with Pfizer Inc. and Merck KGaA, Darmstadt,
Germany, for ovarian cancer. SNDX-6352 is being evaluated in a
single ascending dose Phase 1 clinical trial and is expected to be
developed to treat a variety of cancers. For more information on
Syndax, please visit www.syndax.com.
Syndax’s Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "may," "will," "expect," "plan,"
"anticipate," "estimate," "intend," "believe" and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to
identify forward-looking statements. These forward-looking
statements are based on Syndax's expectations and assumptions as of
the date of this press release. Each of these forward-looking
statements involves risks and uncertainties. Actual results may
differ materially from these forward-looking statements.
Forward-looking statements contained in this press release include,
but are not limited to, statements about the progress, timing,
clinical development and scope of clinical trials and the reporting
of clinical data for Syndax's product candidates, and the potential
use of SNDX-6352 to treat various cancer indications. Many factors
may cause differences between current expectations and actual
results including unexpected safety or efficacy data observed
during preclinical or clinical studies, clinical trial site
activation or enrollment rates that are lower than expected,
changes in expected or existing competition, changes in the
regulatory environment, failure of Syndax's collaborators to
support or advance collaborations or product candidates and
unexpected litigation or other disputes. Other factors that may
cause Syndax's actual results to differ from those expressed or
implied in the forward-looking statements in this press release are
discussed in Syndax's filings with the U.S. Securities and Exchange
Commission, including the "Risk Factors" sections contained
therein. Except as required by law, Syndax assumes no obligation to
update any forward-looking statements contained herein to reflect
any change in expectations, even as new information becomes
available.
Investor Contact:
Heather Savelle
Argot Partners
heather@argotpartners.com
Tel 646.395.3734
Media Contact:
Eliza Schleifstein
Argot Partners
eliza@argotpartners.com
Tel 917.763.8106
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Apr 2023 to Apr 2024